SIR-9900 is under clinical development by Sironax and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SIR-9900’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SIR-9900 overview
SIR-9900 is under development for the treatment of inflammatory diseases, particularly in central nervous system and degenerative diseases, particularly in central nervous system. It acts by targeting receptor interacting serine/threonine protein kinase 1 (RIP1). It is administered through oral route.
Sironax overview
Sironax is a clinical-stage biotechnology company that discovers and develops transformational therapies that treat age-related degenerative diseases. The company’s pipeline includes SIR2446 and SIR9900. Sironax pipeline programs focus on key mechanisms underlying age-related degenerative diseases including regulated cell death, neuroprotective pathways, and neuroinflammation. The company has operations in the US, Australia, and China. Sironax is headquartered in Beijing, China.
For a complete picture of SIR-9900’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
